COVID vaccine passports to start in England this month
September 6, 2021Medical Communications, Sales and Marketing
The Vaccine Minister, Nadhim Zahawi, has confirmed that vaccine passports will be required in nightclubs and other indoor venues at …
Bimekizumab receives first positive health technology assessment worldwide
September 6, 2021Sales and Marketing
NICE has published its final Technology Appraisal Guidance (TAG) recommending UCB’s BIMZELX (bimekizumab) as a treatment option for adults with …
Newron begins first potentially pivotal schizophrenia study
September 6, 2021Sales and Marketing
Newron has initiated Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia.Study 008A, a four-week, randomised, …
WHO: Number of dementia sufferers to rise 40% to 78 million by 2030
September 3, 2021Medical Communications
A new report from the WHO has predicted the number of people suffering from dementia is set to rise by …
NICE approves secukinumab for young people with severe plaque psoriasis
September 3, 2021Medical Communications
NICE has approved secukinumab (Cosentyx) as an option for treating moderate to severe plaque psoriasis in people aged six to …
Novartis halts kidney transplant drug trial
September 3, 2021Medical Communications
Novartis has announced that trials investigating CFZ533 (iscalimab) in kidney transplant patients has been halted after interim data show it …
AstraZeneca’s Ultomiris approved for use on children in EU
September 3, 2021Medical Communications, Research and Development
AstraZeneca has gained EU approval for its rare blood disorder drug, Ultomiris, for use in children. The drug was developed …
US Congress to investigate FDA’s approval of Biogen’s Alzheimer’s drug
September 3, 2021Medical Communications
The US Congress has requested data and documents from the FDA in relation to its accelerated approval of the controversial …
Purdue pharma to pay billions for opioid pandemic but gains immunity in deal
September 2, 2021A US judge has approved Purdue Pharma’s, the makers of Oxycontin, reorganisation plan, which will offer them immunity from any …
Risk of long COVID halved by vaccines, study finds
September 2, 2021Medical Communications
Researchers at King’s College London have found that being fully vaccinated against COVID-19 not only cuts the risk of catching …
Moderna recall COVID vaccines after stainless steel contaminants found
September 2, 2021Medical Communications
Moderna and Takeda Pharmaceutical on Wednesday said they are working with Japanese authorities to recall three batches of their COVID-19 …
FDA seeks new warnings on arthritis drugs
September 2, 2021Medical Communications
The FDA has requested that Pfizer, Eli Lilly, and AbbVie include additional warnings on their arthritis drugs about the risks …
Moderna submits data to FDA for COVID-19 vaccine booster
September 2, 2021Moderna has initiated its submission to the FDA for the evaluation of a booster dose of the Moderna COVID-19 vaccine. …
NICE and Cochrane to collaborate on living recommendations
September 1, 2021Medical Communications, Research and Development
NICE has announced a collaboration with Cochrane, in which Cochrane will help deliver ‘living’ recommendations across the NICE guideline portfolio. …
Viper venom found to inhibit COVID virus from multiplying
September 1, 2021Medical Communications, Research and Development
Brazilian researchers have found that a molecule in the venom of a jararacussu pit viper can prevent coronavirus reproduction. The …
AI test screens for COVID-19 26% faster than lateral flow tests
September 1, 2021Research and Development
A University of Oxford-led study has shown that COVID-19 screening results were available 45 minutes after patients arrived in the …
Fourth contaminated Moderna vial found in Japan
September 1, 2021Medical Communications, Research and Development
A fourth contamination case in less than a week in Japan has been reported involving Moderna’s COVID-19 vaccine, which threatens …
NICE approves life-saving cholesterol drug for NHS
September 1, 2021Research and Development
NICE has approved the ground-breaking cholesterol-lowering drug inclisiran, made by Novartis, for use on the NHS. This is an option …
Empagliflozin demonstrates significant improvement in heart failure outcomes
August 31, 2021Manufacturing and Production
Empagliflozin (Jardiance) showed a significant 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalisation for …
Dupilumab significantly reduces atopic dermatitis in children
August 31, 2021Manufacturing and Production
A pivotal Phase III trial evaluating dupilumab for the treatment of children aged six months to five years with moderate-to-severe …
Latest content
